カテゴリ： GlobalData, カナダ, 企業調査

Novelion Therapeutics Inc (NVLN)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Novelion Therapeutics Inc (NVLN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C3440
◆発行会社（調査会社）：GlobalData
◆発行日：2018年8月
◆ページ数：74
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：カナダ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Novelion Therapeutics Inc (Novelion), formerly QLT Inc, is a biopharmaceutical company that focuses on the development and commercialization of products and solutions for the treatment of people living with rare diseases. The company has two marketed products – Lomitapide, a small molecule microsomal triglyceride transfer protein inhibitor under the brand name JUXTAPID, and Metreleptin, a recombinant analog of human leptin under the brand name MYALEPT. Its other product candidate, zuretinol acetate, is an oral synthetic retenoid that can be used in the treatment of inherited retinal diseases. The company operates along with its subsidiaries across North America, South America, Europe and Asia. Novelion is headquartered in Vancouver, British Columbia, Canada.

Novelion Therapeutics Inc (NVLN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Novelion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Novelion Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Novelion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Novelion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Novelion Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 11
Novelion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Novelion Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Aegerion Pharma Acquires Rights to Myalept from Amylin Pharma 13
Licensing Agreements 14
Aegerion Pharma Expands Licensing Agreement with Amryt Pharma 14
Equity Offering 15
QLT to Raise USD22 Million in Private Placement of Shares 15
Aralez Pharma Raises USD45 Million in Private Placement of Shares 17
Aegerion Pharma Completes Public Offering Of Common Stock For US$83 Million 19
Aegerion Pharma Completes Public Offering Of Common Stock For US$56 Million 20
Debt Offering 22
Aegerion Pharma Raises USD325 Million in Private Placement of Notes Due 2019 22
Asset Transactions 23
Mati Therapeutics Completes Acquisition Of Punctal Plug Delivery System From QLT For Up To US$21 Million 23
Valeant Pharma Acquires Visudyne Business From QLT For Up To USD132.5 Million 24
Acquisition 25
QLT Acquires Aegerion Pharma 25
Novelion Therapeutics Inc – Key Competitors 27
Novelion Therapeutics Inc – Key Employees 28
Novelion Therapeutics Inc – Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Recent Developments 31
Financial Announcements 31
Aug 07, 2018: Novelion Therapeutics Reports Second Quarter 2018 Financial Results 31
May 10, 2018: Novelion Therapeutics Reports First Quarter 2018 Financial Results 34
Mar 15, 2018: Novelion Therapeutics Announces Fourth Quarter And Full Year 2017 Financial Results 35
Nov 09, 2017: Novelion Therapeutics Reports Third Quarter 2017 Financial Results and Announces Leadership Change 37
Aug 08, 2017: Novelion Therapeutics Reports Second Quarter 2017 Financial Results 39
May 09, 2017: Novelion Therapeutics Reports First Quarter 2017 Financial Results 42
Mar 15, 2017: Novelion Therapeutics Reports Preliminary Fourth Quarter & Full Year 2016 Financial Results 44
Jan 09, 2017: Novelion Therapeutics Reports Preliminary 2016 Net Product Sales and Provides 2017 Outlook 47
Corporate Communications 48
Jul 03, 2018: Novelion Therapeutics Names Mark Corrigan As Executive Chair Of The Board Of Directors 48
Dec 04, 2017: Novelion Therapeutics Appoints Michael Price as Senior Vice President and Chief Financial Officer 49
Oct 31, 2017: Novelion Therapeutics Expands Leadership Team with Appointment of Jeffrey Hackman as Chief Operating Officer 50
Sep 11, 2017: Novelion Therapeutics Appoints Suzanne Bruhn, Ph.D. to Board of Directors 51
Aug 02, 2017: Novelion Therapeutics Appoints Mark DiPaolo to Board of Directors 52
Jun 01, 2017: Novelion Therapeutics Appoints John J. Orloff, M.D., to Its Board of Directors, Steps Down as EVP, Head of R&D 53
Apr 19, 2017: Novelion Therapeutics’ Request to Voluntarily Delist from the Toronto Stock Exchange Granted 54
Mar 31, 2017: Novelion Therapeutics Appoints Mark Corrigan, M.D. to Board of Directors 55
Legal and Regulatory 56
Jan 30, 2018: Novelion Therapeutics Announces Sentencing of Subsidiary Aegerion Pharmaceuticals 56
Product News 57
09/22/2017: Criminal and civil actions filed against Aegerion Pharmaceuticals 57
09/15/2017: Metreleptin and Lipodystrophy Data Presented at the International Meeting of Pediatric Endocrinology 58
07/25/2017: Newly Published Long-term Study Shows Highly Positive Results for Lojuxta 59
06/12/2017: Novelion Therapeutics Announces Presentation of Metreleptin Data at American Diabetes Association 60
05/05/2017: Novelion Therapeutics Announces Presentation of Metreleptin Data at American Association of Clinical Endocrinology 61
04/04/2017: Metreleptin and Lipodystrophy Data Presented at the Annual Meeting of the Endocrine Society 62
03/30/2017: Novelion Therapeutics Subsidiary Announces New Data to be Presented at the Annual Meeting of the Endocrine Society 64
03/06/2018: Amryt Pharma: Senior Management Appointment 66
01/23/2017: Novelion Therapeutics Announces Acceptance of Marketing Authorization Application for Metreleptin by European Medicines Agency 67
Clinical Trials 68
Apr 27, 2017: Study Results of ‘Real-World’ Experience of Lojuxta (lomitapide) Shows Improved Efficacy Over Clinical Trials of the Drug 68
Other Significant Developments 70
Aug 23, 2018: Novelion Therapeutics announces next phase of operational improvements 70
Feb 28, 2018: Novelion Therapeutics Observes Rare Disease Day 71
Jan 24, 2018: Novelion Therapeutics Announces Cost Reduction Plans and Capital Structure Review 72
Nov 21, 2017: Novelion Therapeutics Provides Update on Agreement between Aegerion Pharmaceuticals and U.S. Department of Justice 73
Appendix 74
Methodology 74
About GlobalData 74
Contact Us 74
Disclaimer 74

List of Tables
Novelion Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Novelion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Novelion Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Novelion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Novelion Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Novelion Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 11
Novelion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Aegerion Pharma Acquires Rights to Myalept from Amylin Pharma 13
Aegerion Pharma Expands Licensing Agreement with Amryt Pharma 14
QLT to Raise USD22 Million in Private Placement of Shares 15
Aralez Pharma Raises USD45 Million in Private Placement of Shares 17
Aegerion Pharma Completes Public Offering Of Common Stock For US$83 Million 19
Aegerion Pharma Completes Public Offering Of Common Stock For US$56 Million 20
Aegerion Pharma Raises USD325 Million in Private Placement of Notes Due 2019 22
Mati Therapeutics Completes Acquisition Of Punctal Plug Delivery System From QLT For Up To US$21 Million 23
Valeant Pharma Acquires Visudyne Business From QLT For Up To USD132.5 Million 24
QLT Acquires Aegerion Pharma 25
Novelion Therapeutics Inc, Key Competitors 27
Novelion Therapeutics Inc, Key Employees 28
Novelion Therapeutics Inc, Other Locations 29
Novelion Therapeutics Inc, Subsidiaries 29

List of Figures
Novelion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Novelion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Novelion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Novelion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Novelion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Novelion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Novelion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Novelion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Novelion Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 11

★海外企業調査レポート[Novelion Therapeutics Inc (NVLN)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Harel Insurance Investments and Financial Services Ltd：企業の戦略・SWOT・財務情報
    Harel Insurance Investments and Financial Services Ltd - Strategy, SWOT and Corporate Finance Report Summary Harel Insurance Investments and Financial Services Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company' …
  • Tractebel Engineering S.A.：企業の戦略的SWOT分析
    Tractebel Engineering S.A. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Terex Corp：企業の戦略・SWOT・財務分析
    Terex Corp - Strategy, SWOT and Corporate Finance Report Summary Terex Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Qatar Electricity & Water Company QSC：発電所・企業SWOT分析
    Qatar Electricity & Water Company QSC - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, informatio …
  • Raytheon Technologies Corp (RTX)：企業の財務・戦略的SWOT分析
    Raytheon Technologies Corp (RTX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • VPK Packaging Group NV：企業の戦略・SWOT・財務情報
    VPK Packaging Group NV - Strategy, SWOT and Corporate Finance Report Summary VPK Packaging Group NV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Pirelli & C. S.p.A.：戦略・SWOT・企業財務分析
    Pirelli & C. S.p.A. - Strategy, SWOT and Corporate Finance Report Summary Pirelli & C. S.p.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • UQM Technologies Inc (UQM)：企業の財務・戦略的SWOT分析
    Summary UQM Technologies Inc (UQM) is a power system manufacturer that offers electric propulsion and generation solutions. The company’s products include fuel cell compression system, aircraft conditioning systems, full electric products, and hybrid components and generators. Its full electric prod …
  • Bank Hapoalim BM：企業の戦略・SWOT・財務情報
    Bank Hapoalim BM - Strategy, SWOT and Corporate Finance Report Summary Bank Hapoalim BM - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • The Lubrizol Corp：企業の戦略的SWOT分析
    The Lubrizol Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • NovaBay Pharmaceuticals Inc (NBY)-製薬・医療分野：企業M&A・提携分析
    Summary NovaBay Pharmaceuticals Inc (NovaBay), formerly NovaCal Pharmaceuticals Inc is a biopharmaceutical company that develops eyecare products. The company’s products include daily lid and lash hygiene spray solution, skin and wound cleanser, and cosetic procedures. Its daily lid and lash hygiene …
  • Saudi Arabian Oil Co：企業の戦略的SWOT分析
    Saudi Arabian Oil Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Macrogen Inc (038290)：企業の財務・戦略的SWOT分析
    Macrogen Inc (038290) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Crown Bioscience Inc：企業のM&A・事業提携・投資動向
    Crown Bioscience Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Crown Bioscience Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A …
  • Qualcomm Incorporated (QCOM)-エネルギー分野：企業M&A・提携分析
    Summary Qualcomm Incorporated (Qualcomm) is a technology and communication company. The company designs and manufactures digital wireless telecommunications products and services. Qualcomm offers integrated circuits and system software for wireless mobile devices. The major technologies such as code …
  • Bukwang Pharm Co Ltd (003000)-製薬・医療分野：企業M&A・提携分析
    Summary Bukwang PharmCo Ltd (BUKWANG) is a pharmaceutical company which develops pharmaceutical products and new drugs. The company’s product portfolio includes levovir, legalon, dexid, thioctacid, lonasen, ixel, Orfil, azeptin, asima among others. Its pipeline products comprise MLR-1023, JM-010, JM …
  • Hoerbiger Holding AG：企業の戦略的SWOT分析
    Hoerbiger Holding AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • FirstEnergy Corp：企業の発電所・SWOT分析2018
    FirstEnergy Corp - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (e …
  • EDF Luminus SA：企業の発電所・SWOT分析2018
    EDF Luminus SA - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (exe …
  • Commerzbank AG：企業のM&A・事業提携・投資動向
    Commerzbank AG - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Commerzbank AG Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestmen …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆